• Non-Small Cell Lung Cancer | Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer with an EGFR Mutation

  • Jun 21 2024
  • Durée: 2 h
  • Podcast

Page de couverture de Non-Small Cell Lung Cancer | Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer with an EGFR Mutation

Non-Small Cell Lung Cancer | Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer with an EGFR Mutation

  • Résumé

  • Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics:

    • Introduction (0:00)
    • Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Langer (2:08)
    • Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation — Dr Goldman (22:37)
    • Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation — Dr Yu (43:23)
    • Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation — Dr Sabari (1:03:33)
    • Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation — Dr Piotrowska (1:20:15)
    • Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation — Dr Neal (1:38:44)

    CME information and select publications

    Voir plus Voir moins
activate_primeday_promo_in_buybox_DT

Ce que les auditeurs disent de Non-Small Cell Lung Cancer | Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer with an EGFR Mutation

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.